Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1988 3
1990 1
1991 1
1992 2
1993 1
1994 1
1995 3
1996 5
1998 2
1999 3
2000 4
2001 1
2002 3
2003 5
2004 2
2005 1
2006 2
2007 6
2008 6
2009 2
2010 4
2011 3
2012 3
2013 9
2014 8
2015 4
2016 3
2017 6
2018 6
2019 5
2020 3
2021 1
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators. Eikelboom JW, et al. N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27. N Engl J Med. 2017. PMID: 28844192 Free article. Clinical Trial.
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, Dreier RF, Sassi-Sayadi M, Haskell LP, Narkiewicz K, Wang JG; PRECISION investigators. Schlaich MP, et al. Lancet. 2022 Dec 3;400(10367):1927-1937. doi: 10.1016/S0140-6736(22)02034-7. Epub 2022 Nov 7. Lancet. 2022. PMID: 36356632 Clinical Trial.
The primary and key secondary endpoints were changes in unattended office systolic blood pressure from baseline to week 4 and from withdrawal baseline to week 40, respectively. Secondary endpoints included 24-h ambulatory blood pressure changes. The study is registered on …
The primary and key secondary endpoints were changes in unattended office systolic blood pressure from baseline to week 4 and from withdrawa …
Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer.
Zhang H, Pandey S, Travers M, Sun H, Morton G, Madzo J, Chung W, Khowsathit J, Perez-Leal O, Barrero CA, Merali C, Okamoto Y, Sato T, Pan J, Garriga J, Bhanu NV, Simithy J, Patel B, Huang J, Raynal NJ, Garcia BA, Jacobson MA, Kadoch C, Merali S, Zhang Y, Childers W, Abou-Gharbia M, Karanicolas J, Baylin SB, Zahnow CA, Jelinek J, Graña X, Issa JJ. Zhang H, et al. Cell. 2018 Nov 15;175(5):1244-1258.e26. doi: 10.1016/j.cell.2018.09.051. Epub 2018 Oct 25. Cell. 2018. PMID: 30454645 Free PMC article.
ELMO1 deficiency enhances platelet function.
Patel A, Kostyak J, Dangelmaier C, Badolia R, Bhavanasi D, Aslan JE, Merali S, Kim S, Eble JA, Goldfinger L, Kunapuli S. Patel A, et al. Blood Adv. 2019 Feb 26;3(4):575-587. doi: 10.1182/bloodadvances.2018016444. Blood Adv. 2019. PMID: 30787021 Free PMC article.
Gastrin-releasing peptide attenuates fear memory reconsolidation.
Murkar A, Kent P, Cayer C, James J, Merali Z. Murkar A, et al. Behav Brain Res. 2018 Jul 16;347:255-262. doi: 10.1016/j.bbr.2017.11.037. Epub 2017 Dec 2. Behav Brain Res. 2018. PMID: 29191578
Although evidence suggests the window of opportunity to alter reactivated consolidation memory can be as long as 6 h, shorter intervals have not been extensively investigated. METHOD: Male Sprague-Dawley rats received six 1.0 mA continuous footshocks. 24 h later, we …
Although evidence suggests the window of opportunity to alter reactivated consolidation memory can be as long as 6 h, shorter interva …
Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder.
Merali SJ, Byon W, Patel YT, Elsrougy A, Marchisin D, Perera V, Chen W, He B, Murthy B. Merali SJ, et al. CPT Pharmacometrics Syst Pharmacol. 2023 Apr;12(4):500-512. doi: 10.1002/psp4.12935. Epub 2023 Mar 5. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36861188 Free PMC article. Clinical Trial.
End points included safety, PKs, and anti-FXa activity. For PKs/PDs, four to six blood samples were collected 26 h postdosing. A population PK model was developed with data from adults and pediatric subjects. ...
End points included safety, PKs, and anti-FXa activity. For PKs/PDs, four to six blood samples were collected 26 h postdosing. A popu …
First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants.
Merali S, Wang Z, Frost C, Meadows-Shropshire S, Hawthorne D, Yang J, Seiffert D. Merali S, et al. Platelets. 2023 Dec;34(1):2222846. doi: 10.1080/09537104.2023.2222846. Platelets. 2023. PMID: 37394920 Free article. Clinical Trial.
Exposure was dose-proportional for BMS-986141 2.5 mg and 150 mg; maximum concentrations were 17.6 ng/mL and 958 ng/mL; and areas under the curve (AUC) to infinity were 183 h* ng/mL and 9207 h* ng/mL, respectively. Mean half-life ranged from 33.7 to 44.7 hours across …
Exposure was dose-proportional for BMS-986141 2.5 mg and 150 mg; maximum concentrations were 17.6 ng/mL and 958 ng/mL; and areas under the c …
105 results